Charles River Laboratories International Inc (NYSE:CRL) Big Money Positioning Change, Sentiment at 1.13

June 29, 2018 - By Nellie Deboer

Charles River Laboratories International, Inc. (NYSE:CRL) Corporate Logo

Positions for Charles River Laboratories International Inc (NYSE:CRL)

“Big money sentiment for Charles River Laboratories International Inc (NYSE:CRL) in Q1 2018 increased to 1.13, SEC.gov filings reveal. That’s up 0.05, from 2017Q4’s 1.08. 140 hedge funds increased and opened new stock positions, while 124 cut down and sold holdings in Charles River Laboratories International Inc so the sentiment is positive. Funds own 44.28 million shares, down from 44.57 million shares in 2017Q4. Funds holding Charles River Laboratories International Inc in top 10 changed to 1 from 2 for a decrease of 1. 31 Investors Sold All; 93 Reduced Holdings; 96 increased stakes while 44 hedge funds bought stakes.

Largest Charles River Laboratories International Inc Shareholders

As of Q1 2018 Channing Capital Management Llc has 2.62% invested in Charles River Laboratories International Inc. As of Q1 2018, 613,141 shares of Charles River Laboratories International Inc are owned by Van Berkom & Associates Inc.. Copper Rock Capital Partners Llc reported 301,980 shares. The Illinois-based fund Ariel Investments Llc have invested about 1.66% of the investment professional’s stock portfolio in Charles River Laboratories International Inc. The Michigan-based fund Norris Perne & French Llp Mi looks positive on Charles River Laboratories International Inc, possessing 99,543 shares.

Charles River Laboratories International, Inc., an early-stage contract research company, provides drug discovery and development services worldwide.The company has $5.40 billion market cap. It operates through three divisions: Research Models and Services , Discovery and Safety Assessment (DSA), and Manufacturing Support (Manufacturing).42.52 is the P/E ratio. The RMS segment produces and sells research model strains primarily genetically and microbiologically defined purpose-bred rats and mice for use by researchers.

The stock increased 1.32% or $1.47 during the last trading session, reaching $112.69.Currently Charles River Laboratories International, Inc. is uptrending after 12.87% change in last June 29, 2017. CRL has 53,270 shares volume. The stock outperformed the S&P 500 by 0.30%.

Charles River Laboratories International, Inc. (NYSE:CRL)’s earnings report is anticipated on August, 8., according to RTT. EPS of $1.47 is 13.95 % up from 2017’s $1.29 EPS. If $1.47 is reported, CRL’s profit will hit $70.43 million for 19.16 P/E. 6.52 % EPS growth is what Wall Street’s predicts after $1.38 reported EPS previous quarter.

Shine Invest Advisory Serv reported 0.02% in Charles River Laboratories International, Inc. (NYSE:CRL). Guggenheim Ltd Com stated it has 139,711 shs or 0.04% of all its holdings. Mason Street Advisors owns 23,822 shs or 0.06% of their US capital. Atria Ltd, a North Carolina-based fund reported 3,722 shs. 3,833 were reported by Ls Investment Advsrs Ltd Co. National Bank Of Ny Mellon invested 0.02% of its capital in Charles River Laboratories International, Inc. (NYSE:CRL). The France-based Bnp Paribas Asset Mngmt Holdings Sa has invested 0.13% in Charles River Laboratories International, Inc. (NYSE:CRL). Amica Retiree Med Tru holds 1,634 shs. Retail Bank has invested 0.03% in Charles River Laboratories International, Inc. (NYSE:CRL). State Treasurer State Of Michigan reported 17,300 shs. Amp Investors accumulated 3,160 shs or 0% of the stock. First Quadrant Lp Ca, a California-based fund reported 6,010 shs. Moreover, Prudential Inc has 0.05% invested in Charles River Laboratories International, Inc. (NYSE:CRL) for 313,254 shs. Genesee Valley Co has invested 0.13% in Charles River Laboratories International, Inc. (NYSE:CRL). Mai Mngmt has invested 0.06% in Charles River Laboratories International, Inc. (NYSE:CRL).

Charles River Laboratories International, Inc. had 24 insider sales and 0 buys since January 2, 2018. This’s net activity of $11.12 million. Barbo William D sold $250,741 worth of Charles River Laboratories International, Inc. (NYSE:CRL) or 2,320 shs on Wednesday, February 21. 300 Charles River Laboratories International, Inc. (NYSE:CRL) shs with value of $34,665 were sold by MASSARO GEORGE. On Monday, February 26 a trade for 3,868 shs valued at $415,224 was made by Smith David Ross. Shares for $890,100 were sold by MILNE GEORGE M JR. Another trade for 9,893 shs valued at $1.08 million was sold by Girshick Birgit. On Thursday, February 15 CHUBB STEPHEN D sold $312,172 worth of Charles River Laboratories International, Inc. (NYSE:CRL).

Charles River Laboratories International, Inc. (NYSE:CRL) Ratings Coverage

Total analysts of 10 have positions in Charles River (NYSE:CRL) as follows: 5 rated it a “Buy”, 0 with “Sell” and 5 with “Hold”. The positive are 50%. Since January 19, 2018 according to StockzIntelligence Inc Charles River has 11 analyst reports. On Wednesday, February 14 the stock has “Overweight” rating by JP Morgan. The stock rating was upgraded by KeyBanc Capital Markets to “Overweight” on Friday, June 15. On Wednesday, February 14 the firm has “Buy” rating by SunTrust given. The company rating was initiated by MUFG Securities Americas Inc on Friday, April 20. On Wednesday, March 14 the stock has “Equal-Weight” rating by Morgan Stanley. On Tuesday, February 13 the stock has “Hold” rating by RBC Capital Markets. In Tuesday, February 13 report Robert W. Baird maintained the stock with “Buy” rating. The stock rating was maintained by Jefferies with “Buy” on Tuesday, April 24. On Monday, January 22 the company was downgraded by SunTrust.

For more Charles River Laboratories International, Inc. (NYSE:CRL) news posted recently go to: Benzinga.com, Benzinga.com, Benzinga.com, Businesswire.com or Seekingalpha.com. The titles are as follows: “Benzinga’s Top Upgrades, Downgrades For June 15, 2018” posted on June 15, 2018, “Charles River Laboratories Is A Leader In Biopharma Outsourcing, KeyBanc Says In Upgrade” on June 15, 2018, “The Market In 5 Minutes: Tariffs, NXPI, Powell And More” with a publish date: June 15, 2018, “Charles River Laboratories to Present at Jefferies and William Blair Conferences” and the last “Venture Capital Deals Of The Week: Ant Financial Gets $14B Ahead Of IPO” with publication date: June 09, 2018.

Charles River Laboratories International, Inc. (NYSE:CRL) Institutional Investors Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.





Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: